Sun Pharma Advanced Research Company Ltd (SPARC):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Sun Pharma Advanced Research Company Ltd (SPARC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3503
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:31
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:インド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Sun Pharma Advanced Research Company Ltd (SPARC), a subsidiary of Sun Pharmaceutical Industries Ltd, is a bio pharmaceutical clinical research and development service provider. The company develops active pharmaceutical ingredients, formulations and drug delivery technologies for the treatment of cancer and inflammatory diseases. Its research category consists of therapeutic focus, delivery technologies, research programs and reserch and development pipeline. SPARC’s therapeutic focus comprises oncology, neuro degeneration, ophthalmology, dermatology and abuse deterrent formulations. The company’s research and development pipeline includes levetiracetam ER, latanoprost BAK Free, salmeterol-fluticasone DPI, baclofen GRS, PICN, brimonidine OD, SDN – 021, SUN – K0706, SUN – 597 Topical, SUN – K0706, minocycline topical, SUN – K0954 and SDP – 037. SPARC is headquartered in Mumbai, Maharashtra, India.

Sun Pharma Advanced Research Company Ltd (SPARC) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Sun Pharma Advanced Research Company Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Sun Pharma Advanced Research Company Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Sun Pharma Advanced Research Company Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Sun Pharma Advanced Research Company Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Sun Pharma Advanced Research Company Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Sun Pharma Advanced Research Company Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Licensing Agreements 10
Sun Pharma Enters into Licensing Agreement with SPARC 10
Sun Pharma Advanced Research Enters Into Licensing Agreement With Sun Pharma 11
Equity Offering 12
Sun Pharma Advanced Plans to Raise Additional Funds in Rights Offering of Shares 12
Sun Pharma Advanced Research Company to Raise USD39 Million in Rights Offering of Shares 13
Sun Pharma Advanced Research Completes Rights Issue Of Shares For US$36 Million 14
Sun Pharma Advanced Research Company Ltd – Key Competitors 16
Sun Pharma Advanced Research Company Ltd – Key Employees 17
Sun Pharma Advanced Research Company Ltd – Locations And Subsidiaries 18
Head Office 18
Recent Developments 19
Corporate Communications 19
Sep 18, 2017: Sun Pharma Advanced Research Company Announces Change in Board of Directors 19
Legal and Regulatory 20
Oct 11, 2017: Sun Pharma Provide Update on USFDA Inspection for Dadra facility 20
Product News 21
11/14/2017: Spains Almirall Warns of Delay in approval for Psoriasis Drug 21
09/20/2017: Sun Pharma Odomzo New Label Approval Shows Sustained Duration of Response of 26 Months in Treatment of Locally Advanced Basal Cell Carcinoma 22
07/26/2018: Almirall receives CHMP’s positive opinion for Ilumetri 23
03/21/2018: Sun Pharma Announces U.S. FDA Approval of ILUMYA (tildrakizumab-asmn) for the Treatment of Moderate-to-Severe Plaque Psoriasis 24
Product Approvals 25
May 24, 2017: Sun Pharma Announces US FDA Filing Acceptance of Biologics License Application (BLA) For Tildrakizumab 25
Mar 24, 2017: Almirall and Sun Pharma Announce Regulatory Filing of Tildrakizumab in Europe 26
Clinical Trials 27
Feb 12, 2018: Sun Pharma Announces Twelve Tildrakizumab Abstracts to be Presented at American Academy of Dermatology 2018 Annual Meeting 27
Jun 06, 2017: Promising new treatment option for chronic plaque psoriasis 29
Mar 01, 2017: Sun Pharma Announces Data from Tildrakizumab Clinical Development Program to be Presented at the 2017 American Academy of Dermatology Meeting 30
Appendix 31
Methodology 31
About GlobalData 31
Contact Us 31
Disclaimer 31

List of Tables
Sun Pharma Advanced Research Company Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Sun Pharma Advanced Research Company Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Sun Pharma Advanced Research Company Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Sun Pharma Advanced Research Company Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Sun Pharma Advanced Research Company Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Sun Pharma Advanced Research Company Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Sun Pharma Enters into Licensing Agreement with SPARC 10
Sun Pharma Advanced Research Enters Into Licensing Agreement With Sun Pharma 11
Sun Pharma Advanced Plans to Raise Additional Funds in Rights Offering of Shares 12
Sun Pharma Advanced Research Company to Raise USD39 Million in Rights Offering of Shares 13
Sun Pharma Advanced Research Completes Rights Issue Of Shares For US$36 Million 14
Sun Pharma Advanced Research Company Ltd, Key Competitors 16
Sun Pharma Advanced Research Company Ltd, Key Employees 17

List of Figures
Sun Pharma Advanced Research Company Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Sun Pharma Advanced Research Company Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Sun Pharma Advanced Research Company Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Sun Pharma Advanced Research Company Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Sun Pharma Advanced Research Company Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Sun Pharma Advanced Research Company Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Sun Pharma Advanced Research Company Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Sun Pharma Advanced Research Company Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Sun Pharma Advanced Research Company Ltd (SPARC):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Wirecard AG:企業の戦略・SWOT・財務分析
    Wirecard AG - Strategy, SWOT and Corporate Finance Report Summary Wirecard AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • EyeGate Pharmaceuticals Inc (EYEG):企業の財務・戦略的SWOT分析
    Summary EyeGate Pharmaceuticals Inc (EyeGate) is a clinical-stage specialty pharmaceutical and drug delivery company that develops and commercializes products for treating diseases and disorders of the eye. The company’s proprietary technology EyeGate II delivery system, utilizes transscleral iontop …
  • Sanofi (SAN):企業の財務・戦略的SWOT分析
    Sanofi (SAN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pote …
  • Shire Plc (SHP):企業の財務・戦略的SWOT分析
    Shire Plc (SHP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Triphase Accelerator Corp:製薬・医療:M&Aディール及び事業提携情報
    Summary Triphase Accelerator Corp (Triphase Accelerator) is a biotechnology development company that acquires and develops novel therapeutics for the treatment of cancer. The company's pipeline products comprise marizomib, a brain-penetrant proteasome inhibitor, which is developed in both intravenou …
  • KornFerry International (KFY):企業の財務・戦略的SWOT分析
    KornFerry International (KFY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • CHC Group LLC:企業の戦略的SWOT分析
    CHC Group LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Oxford Metrics plc (OMG):企業の財務・戦略的SWOT分析
    Oxford Metrics plc (OMG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Centre for Drug Research and Development:製薬・医療:M&Aディール及び事業提携情報
    Summary Centre for Drug Research and Development (CDRD) is a drug development and commercialization center that provides scientific infrastructure to transform discoveries into innovative therapeutic products and improved health outcomes. The center's drug development platform includes target valida …
  • Medical Developments International Ltd (MVP):製薬・医療:M&Aディール及び事業提携情報
    Summary Medical Developments International Ltd (MDI) is a healthcare company that develops, manufactures and markets pain relief and respiratory medicine. The company provides products such as penthrox, asthma and COPD, medical devices and veterinary products. It offers asthma and COPD products whic …
  • Agilent Technologies Inc (A):医療機器:M&Aディール及び事業提携情報
    Summary Agilent Technologies Inc (Agilent) is a provider of instruments, reagents, software, services and consumables for comprehensive laboratory workflow. Its product portfolio comprises atomic absorption systems, bioanalyzers, gene expression microarrays and automation systems, among others. The …
  • Monteloeder S.L.:企業の戦略・SWOT・財務情報
    Monteloeder S.L. - Strategy, SWOT and Corporate Finance Report Summary Monteloeder S.L. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Opthea Ltd (OPT)-医療機器分野:企業M&A・提携分析
    Summary Opthea Ltd (Opthea), formerly Circadian Technologies Ltd is a provider of research and development of angiogenesis and vascular leakage-based treatments for cancer focusing on vascular endothelial growth factors. The company’s pipeline products comprise VEGF-C, VEGF-D and VEGFR-3. Opthea’s d …
  • Asahi Kasei Pharma Corp:製薬・医療:M&Aディール及び事業提携情報
    Summary Asahi Kasei Pharma Corp (Asahi Kasei Pharma), a subsidiary of Asahi Kasei Corp, discovers, develops, manufactures, and markets pharmaceuticals and diagnostic products. The company's portfolio encompasses prescription drugs, diagnostic reagents, and enzymes for diagnostic reagents. Its prescr …
  • Sejal Glass Limited (SEZAL):企業の財務・戦略的SWOT分析
    Sejal Glass Limited (SEZAL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Furukawa Electric Co., Ltd.:企業の戦略・SWOT・財務分析
    Furukawa Electric Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Furukawa Electric Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Serinus Energy plc (SEN):企業の財務・戦略的SWOT分析
    Summary Serinus Energy plc (Serinus), formerly Serinus Energy Inc, is an oil and gas company. It carries out exploration, development, and production of crude oil and natural gas assets in Romania and Tunisia. The company holds interest and operates Satu Mare Concession, an oil and gas exploration b …
  • Surge Energy Inc (SGY):企業の財務・戦略的SWOT分析
    Summary Surge Energy Inc (Surge) is an oil and gas company that offers acquisitions, exploration and production of crude oil and natural gas reserves. The company provides risk management and risk development drilling services. Its oil and natural gas producing properties include Shaunavon and Dodsl …
  • Inivata Ltd:製品パイプライン分析
    Summary Inivata Ltd (Inivata) is a clinical cancer genomics company that utilizes the precision of circulating tumor DNA analysis to improve personalized healthcare in oncology. The company uses liquid biopsy platform, to identify and characterize ctDNA through a non-invasive blood test. Its liquid …
  • Altaba Inc.:企業のM&A・事業提携・投資動向
    Altaba Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Altaba Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, ca …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆